ICON Public Limited Company (ICLR)
$164.34-0.04%Close
SELLRECOVERY · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $12.6B
- Beta
- 1.24
- P/E (TTM)
- 38.30
- Short % float
- 3.67%
- Days to cover
- 2.5
- SI change
- +6.6%
- 1W
- +1.64%
- 1M
- -2.72%
- vs SPY 1W
- +1.78%
- vs SPY 1M
- -5.22%
Industry peers
FMP comparable companies · ranked by market cap
- WUXIFWuXi AppTec Co., Ltd.$80.1B$26.85
- 300759.SZPharmaron Beijing Co., Ltd.$64.6B$43.75
- IQVSELLIQVIA Holdings Inc.$42.6BBEARQ 24$258.88-0.58%
- 603127.SSJoinn Laboratories(China)Co.,Ltd.$39.0B$52.06
- LHSELLLabcorp Holdings Inc.$25.8BBEARQ 10$314.20-0.60%
- MEDPSELLMedpace Holdings, Inc.$16.8BBULLQ 47$602.70-1.64%
- CRLBUYCharles River Laboratories International, Inc.$14.4BBULLQ 12$298.00-0.94%
- HNGZYHangzhou Tigermed Consulting Co., Ltd$6.9B$4.45
- FTREBUYFortrea Holdings Inc.$1.9BBULLQ -1$20.37-0.38%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 55
- VALUE
- 37
- GROWTH
- 49
- GARP
- 66
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC2.1%
REV YoY-
ROE3.5%
EPS YoY-
ROA2.0%
GROSS22
OP10
NET4
[VALUATION]
P/E TTM38.30
P/E FWD15.68
SECTOR PE20.34
INDUSTRY PE31.41
P/B1.35
P/FCF-
EV/EBITDA12.17
EV/EBIT-
PEG1.38
FCF YIELD-
RISK
INT COV-
D/E37.25
ALTMAN Z-
CURR RATIO0.95
ND/EBITDA-
BETA1.24
Company news
FAQ
- What is LOPJLB’s current signal on ICLR?
- LOPJLB’s latest quantitative signal on ICON Public Limited Company (ICLR) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is ICLR in?
- ICON Public Limited Company (ICLR) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does ICON Public Limited Company (ICLR) do?
- ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical s…